Industry
Biotechnology
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Loading...
Open
76.00
Mkt cap
12B
Volume
243K
High
77.62
P/E Ratio
79.81
52-wk high
85.57
Low
75.02
Div yield
0.00
52-wk low
61.16
Portfolio Pulse from
December 02, 2024 | 12:30 pm
Portfolio Pulse from
November 29, 2024 | 5:45 pm
Portfolio Pulse from
November 25, 2024 | 2:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 7:16 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 11:51 am
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 11:51 am
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 10:32 am
Portfolio Pulse from Benzinga Insights
October 29, 2024 | 2:01 pm
Portfolio Pulse from Benzinga Newsdesk
September 18, 2024 | 11:07 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.